Puerarin Enhances the Sensitivity of Colorectal Cancer to 5‐Fluorouracil and Oxaliplatin by Inhibiting the PTEN/PI3K/AKT Signaling Pathway
Journal of Biochemical and Molecular Toxicology · 2025-10 · 39 (10)
DOI: 10.1002/jbt.70517 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 25.09.2025. Verfasst von Xiaowei Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xi'an Eighth Hospital, Xian, P.R. China. Hauptthemen laut MEDLINE: Isoflavones, PTEN Phosphohydrolase, Fluorouracil, Oxaliplatin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Colorectal cancer (CRC) represents the most prevalent malignancy within the gastrointestinal system, with metastatic cases comprising approximately 50% of all CRC diagnoses. While chemotherapy remains the cornerstone treatment for metastatic CRC, the emergence of chemoresistance has significantly limited the clinical efficacy of 5‐fluorouracil (5‐FU) and oxaliplatin‐based regimens. In this study, we systematically investigated the therapeutic potential of puerarin in CRC management, focusing on its antitumor properties and chemosensitization effects. Our findings demonstrate that puerarin exhibits significant antitumor activity both in vitro and in vivo, while also potentiating the therapeutic effects of 5‐FU and oxaliplatin through synergistic interactions. Mechanistically, we identified PTEN as a critical molecular target of puerarin, evidenced by the reversal of puerarin‐mediated effects upon PTEN knockdown. Further molecular characterization revealed that puerarin exerts its antitumor effects through PTEN‐mediated suppression of AKT activation and subsequent induction of apoptotic pathways. Importantly, we established that puerarin enhances CRC cell sensitivity to 5‐FU and oxaliplatin via modulation of the PTEN/PI3K/AKT signaling axis. These findings not only elucidate a novel molecular mechanism underlying puerarin's anti‐CRC activity but also provide a promising therapeutic strategy for overcoming chemoresistance in CRC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Xi'an Eighth Hospital, Xian, P.R. China.
- Department of Clinical Pharmacy, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, P.R. China.
- Department of Gastrointestinal Surgery, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, P.R. China.
ORCID-Profile: Yanrui Zhang
Zitieren
APA
Wang, X., Yang, X., Wang, J., Zhang, Y., & Zhang, Y. (2025). Puerarin Enhances the Sensitivity of Colorectal Cancer to 5‐Fluorouracil and Oxaliplatin by Inhibiting the PTEN/PI3K/AKT Signaling Pathway. Journal of Biochemical and Molecular Toxicology, 39(10). https://doi.org/10.1002/jbt.70517
Vancouver
Wang X, Yang X, Wang J, Zhang Y, Zhang Y. Puerarin Enhances the Sensitivity of Colorectal Cancer to 5‐Fluorouracil and Oxaliplatin by Inhibiting the PTEN/PI3K/AKT Signaling Pathway. Journal of Biochemical and Molecular Toxicology. 2025;39(10). doi:10.1002/jbt.70517
BibTeX
@article{Wang2025,
author = {Wang, Xiaowei and Yang, Xiaorui and Wang, Jiang and Zhang, Yueli and Zhang, Yanrui},
title = {Puerarin Enhances the Sensitivity of Colorectal Cancer to 5‐Fluorouracil and Oxaliplatin by Inhibiting the PTEN/PI3K/AKT Signaling Pathway},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2025},
volume = {39},
number = {10},
doi = {10.1002/jbt.70517}
}
EUVIMED